Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shea
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF	Terminated	3	372	Europe, US, RoW	Pamrevlumab, FG-3019, Placebo	FibroGen	Idiopathic Pulmonary Fibrosis	09/23	09/23
Goverman, Jeremy
NCT03695939: Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds	Completed	1/2	25	US	realSKIN (skin xenotransplant), Human Cadaver Allograft, Human Allograft Skin, HCA	XenoTherapeutics, Inc., Massachusetts General Hospital, Joseph M. Still Research Foundation, Inc.	Deep Full-thickness Burn Injury (Disorder)	12/23	12/23
NCT04040660: Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries	Approved for marketing	N/A		US	NexoBrid	MediWound Ltd	Thermal Burn
ABRUPT2, NCT04356859: The Acute Burn ResUscitation Multicenter Prospective Trial	Recruiting	N/A	400	Canada, US	Albumin Human, albumin	American Burn Association, United States Department of Defense	Burn Injury	08/25	09/25